MicroRNA expression profiles identify subtypes of mantle cell lymphoma with different clinicobiological characteristics

Clinical Cancer Research

Volumn 19, Issue 12, 2013, Pages 3121-3129

  Navarro, Alba ^a   Clot, Guillem ^a   Prieto, Miriam ^a   Royo, Cristina ^a   Vegliante, Maria Carmela ^a   Amador, Virginia ^a   Hartmann, Elena ^b   Salaverria, Itziar ^a   Beá, Sílvia ^a   Martín Subero, Jose Ignacio ^c   Rosenwald, Andreas ^b   Ott, German ^d   Wiestner, Adrian ^e   Wilson, Wyndham H ^f   Campo, Elías ^a   Hernández, Luis ^a  

^a INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^b UNIVERSITY OF WÜRZBURG   (Germany)

^c UNIVERSITY OF BARCELONA   (Spain)

^d ROBERT BOSCH HOSPITAL   (Germany)

^e National Heart Lung and Blood Institute   (Germany)

^f NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CD40 ANTIGEN; IMMUNOGLOBULIN HEAVY CHAIN; MICRORNA; MICRORNA 149; MICRORNA 190; MICRORNA 34A; MICRORNA 455 3P; MICRORNA 455 5P; MICRORNA 483 5P; MICRORNA 565; MICRORNA 649; MICRORNA 708; TRANSCRIPTION FACTOR SOX11; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CARCINOGENESIS; CHROMATIN; CLINICAL ARTICLE; DNA DAMAGE; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE MUTATION; HUMAN; HUMAN TISSUE; MALE; MANTLE CELL LYMPHOMA; ONCOGENE MYC; PRIORITY JOURNAL; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOGLOBULINS; LYMPH NODES; LYMPHOMA, MANTLE-CELL; MALE; MICRORNAS; MIDDLE AGED; MUTATION; PROGNOSIS; SIGNAL TRANSDUCTION; SOXC TRANSCRIPTION FACTORS;

EID: 84879494573     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-3077     Document Type: Article

References (39)

1. Engels BM, Hutvagner G. Principles and effects of microRNA-mediated post-transcriptional gene regulation. Oncogene 2006;25:6163-9.
2. Lim LP, Lau NC, Garrett-Engele P, Grimson A, Schelter JM, Castle J, et al. Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature 2005;433:769-73.
3. Miska EA. How microRNAs control cell division, differentiation and death. Curr Opin Genet Dev 2005;15:563-8.
4. Esquela-Kerscher A, Slack FJ. Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer 2006;6:259-69.
5. Huppi K, Volfovsky N, Mackiewicz M, Runfola T, Jones TL, Martin SE, et al. MicroRNAs and genomic instability. Semin Cancer Biol 2007; 17:65-73.
6. Calin GA, Croce CM. MicroRNAs and chromosomal abnormalities in cancer cells. Oncogene 2006;25:6202-10.
7. Fabbri M, Croce CM. Role of microRNAs in lymphoid biology and disease. Curr Opin Hematol 2011;18:266-72.
8. Bosch F, Jares P, Campo E, Lopez-Guillermo A, Piris MA, Villamor N, et al. PRAD-1/cyclin D1 gene overexpression in chronic lymphoproliferative disorders: a highly specific marker of mantle cell lymphoma. Blood 1994;84:2726-32.
9. Royo C, Salaverria I, Hartmann EM, Rosenwald A, Campo E, Bea S. The complex landscape of genetic alterations in mantle cell lymphoma. Semin Cancer Biol 2011;21:322-34.
10. Jares P, Colomer D, Campo E. Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for newtargeted therapeutics. Nat Rev Cancer 2007;7:750-62.
11. Di Lisio L, Gomez-Lopez G, Sanchez-Beato M, Gomez-Abad C, Rodriguez ME, Villuendas R, et al. Mantle cell lymphoma: transcriptional regulation by microRNAs. Leukemia 2010;24:1335-42.
12. Zhao JJ, Lin J, Lwin T, Yang H, Guo J, Kong W, et al. microRNA expression profile and identification of miR-29 as a prognostic marker and pathogenetic factor by targeting CDK6 in mantle cell lymphoma. Blood 2010;115:2630-9.
13. Fernandez V, Salamero O, Espinet B, Sole F, Royo C, Navarro A, et al. Genomic and gene expression profiling defines indolent forms of mantle cell lymphoma. Cancer Res 2010;70:1408-18.
14. Navarro A, Clot G, Royo C, Jares P, Hadzidimitriou A, Agathangelidis A, et al. Molecular subsets of mantle cell lymphoma defined by the IGHV mutational status and SOX11 expression have distinct biological and clinical features. Cancer Res 2012;72:5307-16.
15. Ondrejka SL, Lai R, Smith SD, Hsi ED. Indolent mantle cell leukemia: a clinicopathological variant characterized by isolated lymphocytosis, interstitial bone marrow involvement, kappa light chain restriction, and good prognosis. Haematologica 2011;96:1121-7.
16. Royo C, Navarro A, Clot G, Salaverria I, Gine E, Jares P, et al. Nonnodal type of mantle cell lymphoma is a specific biological and clinical subgroup of the disease. Leukemia 2012;26:1895-8.
17. Rule SA, Poplar S, Evans PA, O'Connor SJ, Owen RG. Indolent mantlecell lymphoma: immunoglobulin variable region heavy chain sequence analysis reveals evidence of disease 10 years prior to symptomatic clinical presentation. J Clin Oncol 2011;29:e437-9.
18. Iqbal J, Shen Y, Liu Y, Fu K, Jaffe ES, Liu C, et al. Genome-wide MicroRNA profiling of mantle cell lymphoma reveal a distinct subgroup with poor prognosis. Blood 2012;119:4939-48.
19. van Dongen JJ, Langerak AW, Bruggemann M, Evans PA, Hummel M, Lavender FL, et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia 2003;17: 2257-317.
20. Wilkerson MD, Hayes DN. Consensus Cluster Plus: a class discovery tool with confidence assessments and item tracking. Bioinformatics 2010;26:1572-3.
21. Monti S, Tamayo P, Mesirov J, Golub T. Consensus clustering: a resampling-based method for class discovery and visualization of gene expression microarray data. Machine learning 2003;52:91-118.
22. Camacho E, Hernandez L, Hernandez S, Tort F, Bellosillo B, Bea S, et al. ATM gene inactivation in mantle cell lymphoma mainly occurs by truncating mutations and missense mutations involving the phosphatidylinositol-3 kinase domain and is associated with increasing numbers of chromosomal imbalances. Blood 2002;99:238-44.
23. Wang Y, Yu Y, Tsuyada A, Ren X, Wu X, Stubblefield K, et al. Transforming growth factor-beta regulates the sphere-initiating stem celllike feature in breast cancer through miR-181 and ATM. Oncogene 2011;30:1470-80.
24. Huang Y, Chuang A, Hao H, Talbot C, Sen T, Trink B, et al. Phospho-Delta Np63alpha is a key regulator of the cisplatin-induced micro-RNAome in cancer cells. Cell Death Differ 2011;18:1220-30.
25. Basso K, Klein U, Niu H, Stolovitzky GA, Tu Y, Califano A, et al. Tracking CD40 signaling during germinal center development. Blood 2004;104: 4088-96.
26. Reimand J, Arak T, Vilo J. g:Profiler-a web server for functional interpretation of gene lists (2011 update). Nucleic Acids Res 2011; 39:W307-W315.
27. Rosenwald A, Wright G, Wiestner A, Chan WC, Connors JM, Campo E, et al. The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell 2003;3:185-97.
28. Chen F, Hu SJ. Effect of microRNA-34a in cell cycle, differentiation, and apoptosis: a review. J Biochem Mol Toxicol 2012;26:79-86.
29. Hartmann E, Fernandez V, Moreno V, Valls J, Hernandez L, Bosch F, et al. Five-gene model to predict survival in mantle-cell lymphoma using frozen or formalin-fixed, paraffin-embedded tissue. J Clin Oncol 2008;26:4966-72.
30. Kienle D, Katzenberger T, Ott G, Saupe D, Benner A, Kohlhammer H, et al. Quantitative gene expression deregulation in mantle-cell lymphoma: correlation with clinical and biologic factors. J Clin Oncol 2007;25:2770-7.
31. Yamamura S, Saini S, Majid S, Hirata H, Ueno K, Chang I, et al. MicroRNA-34a suppresses malignant transformation by targeting c-Myc transcriptional complexes in human renal cell carcinoma. Carcinogenesis 2012;33:294-300.
32. Wang X, Liu P, Zhu H, Xu Y, Ma C, Dai X, et al. miR-34a, a microRNAupregulated in a double transgenic mouse model of Alzheimer's disease, inhibits bcl2 translation. Brain Res Bull 2009;80:268-73.
33. Christoffersen NR, Shalgi R, Frankel LB, Leucci E, Lees M, Klausen M, et al. p53-independent upregulation of miR-34a during oncogeneinduced senescence represses MYC. Cell Death Differ 2010;17: 236-45.
34. Navarro A, Bea S, Fernandez V, Prieto M, Salaverria I, Jares P, et al. MicroRNA expression, chromosomal alterations, and immunoglobulin variable heavy chain hypermutations in Mantle cell lymphomas. Cancer Res 2009;69:7071-8.
35. Kastan MB, Lim DS. The many substrates and functions of ATM. Nat Rev Mol Cell Biol 2000;1:179-86.
36. Han BW, Feng DD, Li ZG, Luo XQ, Zhang H, Li XJ, et al. A set of miRNAs that involve in the pathways of drug resistance and leukemic stem-cell differentiation is associated with the risk of relapse and glucocorticoid response in childhood ALL. Hum Mol Genet 2011;20:4903-15.
37. Monk CE, Hutvagner G, Arthur JS. Regulation of miRNA transcription in macrophages in response to Candida albicans. PLoS ONE 2010;5: e13669.
38. Morin RD, Mendez-Lago M, Mungall AJ, Goya R, Mungall KL, Corbett RD, et al. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature 2011;476:298-303.
39. Orchard J, Garand R, Davis Z, Babbage G, Sahota S, Matutes E, et al. A subset of t(11;14) lymphoma with mantle cell features displays mutated IgVH genes and includes patients with good prognosis, nonnodal disease. Blood 2003;101:4975-81. Cooperativa en Cáncer Cooperativa en Cáncer